Therefore, we compared the activation profile of DCs when they were challenged with sorted CD4+ T cells (1:5 ratio) from patients with MS, patients with HIMS, and HC, respectively, in a MLR assay as previously reported [27]. The gene discussed is CD4; the disease is myeloid sarcoma.